For the makers of generic and innovative drugs, Central Europe’s six countries represent a valuable market.
The market, however, is being redrawn by legislative and regulatory actions that change everything from reimbursement policy (and margins), to drug patent expiry and data exclusivity periods. Add in challenges from counterfeit drugs and new patient and physician mindsets, and “business as usual” can put even established players at risk.
Here is how to understand this new market environment — and spot where your own best opportunities exist.
Here is your complete guide to how new laws, regulations and physician and patient attitudes are reshaping Central Europe’s market for generic and innovative drugs.
Market values, medicines and more. This one clearly written report explains exactly how legislative developments occurring in all six Central European countries will affect market value, regulatory framework, sales of specific products, and the fortunes of key generics and innovative drug companies between now and 2014.
Buy now for the insider facts, analysis and forecasts to profit in Central Europe’s changing markets for generic and innovative drugs, including:
Buy now for the current, unbiased information you need to identify which Central European countries have the greatest potential for international generic and innovative drug makers — and which countries are legal and regulatory mine fields.
Generic and Innovative Drugs Market in Central Europe 2012: Comparative Analysis, Reimbursement Policies and Development Forecasts for 2012-2014 is offered by FDAnews in a 303-page PDF format: $3,500 for single user; $5,250 for 5-user license. Site and global licenses available. Contact Customer Service for a quote or more information.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing